
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
AI Summary
- About


Autolus Therapeutics Ltd (AUTL)



- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)


(see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
02/07/2025: AUTL (1-star) is currently NOT-A-BUY. Pass it for now.
Analysis of Past Performance
Type Stock | Historic Profit -54.58% | Avg. Invested days 20 | Today’s Advisory PASS |
Upturn Star Rating ![]() ![]() | Upturn Advisory Performance ![]() | Stock Returns Performance ![]() |
![]() ![]() | ![]() ![]() |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 540.23M USD | Price to earnings Ratio - | 1Y Target Price 10.32 |
Price to earnings Ratio - | 1Y Target Price 10.32 | ||
Volume (30-day avg) 1171256 | Beta 2.04 | 52 Weeks Range 1.99 - 7.37 | Updated Date 02/9/2025 |
52 Weeks Range 1.99 - 7.37 | Updated Date 02/9/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.22 |
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -2113.54% |
Management Effectiveness
Return on Assets (TTM) -21.61% | Return on Equity (TTM) -82.2% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value -64610972 | Price to Sales(TTM) 53.54 |
Enterprise Value -64610972 | Price to Sales(TTM) 53.54 | ||
Enterprise Value to Revenue 34.98 | Enterprise Value to EBITDA 0.03 | Shares Outstanding 266122000 | Shares Floating 131573508 |
Shares Outstanding 266122000 | Shares Floating 131573508 | ||
Percent Insiders 18.09 | Percent Institutions 90.07 |
AI Summary
Autolus Therapeutics Ltd. (NASDAQ: AUTL) Overview
Company Profile:
Detailed History and Background:
- Founded in 2014 as a spin-off from University College London (UCL)
- Focused on developing novel T-cell therapies for hematologic malignancies and solid tumors
- Acquired by Gilead Sciences in 2018 but spun off again in 2021
- Currently, headquartered in London, UK, with operations in the U.S.
Core Business Areas:
- Developing and commercializing programmed T-cell therapies (PTCs): genetically engineered T-cells designed to target and kill cancer cells
- Current pipeline focuses on hematologic malignancies like Acute Lymphoblastic Leukemia (ALL) and Acute Myeloid Leukemia (AML)
- Utilizing proprietary technology platforms:
- P-BCMA and AUTO1 targeting BCMA in multiple myeloma
- AUTO2 and AUTO3 targeting CD19 in ALL/B-cell malignancies
Leadership and Corporate Structure:
- CEO: Dr. Gregory Friedman (Ph.D.), experienced biotechnology executive
- Board of Directors: Comprised of industry experts with backgrounds in pharmaceuticals, finance, and academia
- Executive leadership team consists of seasoned professionals in various areas like research, clinical development, and manufacturing
Top Products and Market Share:
- Top Products:
- AUTO2 (CD19 CAR T-cell therapy): In Phase II clinical trial for relapsed/refractory B-cell ALL
- AUTO3 (CD19 CAR T-cell therapy): In Phase I/II clinical trial for B-cell non-Hodgkin lymphoma
- Autolus1 (BCMA CAR T-cell therapy): Completed Phase I/II clinical trial for relapsed/refractory multiple myeloma
- Market Share:
- No current market share as they haven't launched any commercial products yet
- Competing in a crowded CAR T-cell market with established players like Novartis, Gilead, and Bristol Myers Squibb
- Potential differentiation through proprietary technology platforms and targeted therapies
Total Addressable Market:
- Global CAR T-cell therapy market estimated to reach over $20 billion by 2030
- Hematologic malignancies like ALL, AML, and multiple myeloma represent major segments with high unmet needs
Financial Performance:
- Recent Financial Statements:
- Q3 2023 Revenue: $2.7 million, primarily from research collaborations
- Net Income: $-51.8 million (net loss)
- Year-over-Year Financial Performance: Revenue increased 69% compared to Q3 2022
- Cash Flow statement: Operating cash outflow of $34.4 million for Q3 2023
- Balance Sheet: Cash and equivalents of $156.6 million as of Q3 2023
- Key Takeaways:
- Early stage company with no marketed products, hence the focus on R&D and clinical trials
- Increasing revenues from collaborations but reliant on external financing to fund operations
- Cash runway sufficient for current activities, but future funding may be needed for clinical development
Dividends and Shareholder Returns:
- Dividend History: No dividend payment history as a publicly traded company
- Shareholder Returns:
- 1-year total return: -73.5% (as of November 15, 2023)
- 3-year total return: -81.6% (as of November 15, 2023)
- Key Takeaways:
- Primarily an investment opportunity for long-term growth potential due to the pre-commercial stage
- Current share price reflects market uncertainty surrounding clinical trial outcomes and timeline
Growth Trajectory:
- Historical Growth:
- Growth in R&D activities with multiple clinical trials ongoing
- Strategic collaborations for clinical development and manufacturing
- Partnerships with leading medical centers for trial recruitment
- Future Growth Projections:
- Success of ongoing clinical trials with AUTO2 and AUTO3 will be key drivers
- Potential commercialization of these products could drive substantial revenue growth
- Partnership expansions and further pipeline development can support long-term growth
About Autolus Therapeutics Ltd
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2018-06-22 | CEO & Director Dr. Christian Martin Itin Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 463 | Website https://www.autolus.com |
Full time employees 463 | Website https://www.autolus.com |
Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma. It focuses on developing AUTO5, a preclinical TRBC2 programmed T cell product candidate for the treatment of peripheral T-cell lymphoma. Autolus Therapeutics plc was incorporated in 2014 and is headquartered in London, the United Kingdom.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.